The MTN partners with key civil society groups and other stakeholders to solicit their views on proposed studies and to discuss issues related to study implementation.
More than 25 clinical research sites on four continents have partnered with the Microbicide Trials Network in the conduct of its clinical trials.
Studies at the Microbicide Trials Network are designed specifically to support the potential licensure and regulatory approval of HIV prevention products for populations most vulnerable to HIV.
The Microbicide Trials Network brings together international investigators and community and industry partners whose work is focused on the rigorous evaluation of promising microbicides.
The Microbicide Trials Network is a U.S. National Institutes of Health-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV.
MTN-033 is launched.
MTN presented preliminary results from the HOPE study (MTN-025) at CROI 2018.
The first-ever study of dapivirine gel as a rectal microbicide has begun.
Study on a vaginal ring for both HIV and pregnancy prevention completed.
A stakeholder consultation was held in April in Johannesburg, South Africa, for MTN-042.
MTN’s Annual Meeting was held March 19-20 in Bethesda, Maryland at the Bethesda North Marriott Hotel & Conference Center.
A stakeholder consultation was held in February in Kisumu, Kenya for the REACH study.
Women’s use of vaginal ring is higher in open-label study, as is level of HIV protection
HIV prevention dapivirine vaginal ring found safe and acceptable in US adolescent girls
U.S. study of dapivirine ring in lactating women finds little drug gets into breast milk
Microbicide Trials Network